Xalnesiran

N/A

Report date: 2025/04/20 20:00:03
NME

Base Information

Drug NameXalnesiran
Drug Alias NameRO-7445482RO7445482RG-6346DCR-HBVSDCR-S219 +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceHBsAg inhibitors
TargetsHepatitis B Surface Antigens
Therapy Area/IndicationsHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaTaiwan +[14] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesDicerna Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRoche R&D Center (China) LtdF. Hoffmann-La Roche LtdDicerna Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A